#Islatravir drug resistance and implications for future #HIV treatment #IDSky #MedSky @iasociety.bsky.social
www.iasusa.org/wp-content/u...

New from the IAS-USA Drug-Resistance Mutations Group: Current #Islatravir Susceptibility Data and Guidance for Clinical Decision-Making as doravarine/islatravir moves closer to approval.
Read more: www.iasusa.org/wp-content/u...
#HIV #IDTwitter #InfectiousDiseases #IASUSA

Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study - PubMed Islatravir qm was generally well-tolerated; decreases in total lymphocytes were observed with islatravir. Original primary efficacy objectives were not assessed due to early study stoppage.

Langwirksame #HIV- Medikamente sind auch zum Schutz vor einer Infektion im Einsatz oder werden erprobt. Eine Studie zu #Islatravir (oral) einmal monatlich wurde gestoppt, weil trotz allgemein guter Verträglichkeit die Zahl der Lymphozyten in der Studiengruppe sank; sie stieg danach wieder an.

i-Base graphic for IAS 2025. The main text reads: Once-weekly oral ART. New research that might make HIV meds even easier to take. At the top is i-Base’s website address: I hyphen base dot info. In the bottom left it says: HIV treatment bulletin. In the bottom right is a white box, containing the words: IAS 2025. 13th to 17th July. Above this is a spiral next to the red AIDS ribbon. There are horizontal strips of the IAS 2025 signature graphics at the top and bottom of the image. They are made up of squares, each containing its own unique pattern based on traditional Rwandan art. The colours used in the image are red, black, white and grey.

24-week phase 2 results of once-weekly oral ART with #ulonivirine + #islatravir, plus other studies on this combination at #IAS2025:

i-base.info/htb/51965

Good efficacy and safety – with a larger phase 2b study already ongoing using 200mg ULO and 2 mg ISL doses.

#HIVsky #HIVtreatment #HIVresearch

A Game-Changer for HIV Prevention? Weekly Islatravir Shows Promise for Post-Exposure Prophylaxis Imagine a single pill that could prevent HIV infection after a potential exposure, removing the burden of a 28-day daily regimen.  Islatravir is an investigational drug developed by Merck for the trea...

A weekly HIV prevention pill? In macaques, 2 doses of Merck's islatravir fully protected against SIV—even one dose helped. Given its long half-life in humans, a single oral dose may be enough for post-exposure protection. go.njmicrobe.org/Y2LKTj #HIV #Merck #Islatravir #PublicHealth

i-Base graphic. The main text in red and dark blue, on a light blue blue background, reads: CROI 2025. Conference on retroviruses and opportunistic infections. Below, in white on a burnt orange background, text reads, San Francisco, California. 9th to 12th March. Next to this is a faint image of the Golden Gate Bridge. In the top left corner is a URL: I hyphen base dot info. In the top right corner is the CROI logo, a colourful illustration of HIV.

i-Base reports from this year’s #CROI2025 conference:

i-base.info/htb/50463

Highlights from the programme include:
- New compounds and combinations for #HIVtreatment
- Access to #PrEP
- #bNAbs and cure-related research
- Weight changes and #GLP1 agonists

#islatravir #lenacapavir #LongActing